The company’s founder Dr Gregory Lambert was a keynote speaker at our recent Probiota Asia Summit in Singapore where he discussed some of the initial findings of the product, which is based on the Hafnia alvei strain.
We caught up with him on camera after his talk where he elaborated on the mice studies and the double-blind, randomised, placebo-controlled clinical trial thatr is currently underway.
In the video Dr Lambert also explains its mechanism of action, discussing how the probiotic mimics a satiety protein, and its origin.
Watch the video to find our more, including the firm’s expansion hopes for APAC.
